ID   KAT-18
AC   CVCL_6303
SY   KAT18; Kat18
DR   BTO; BTO_0005161
DR   cancercelllines; CVCL_6303
DR   Cosmic; 886552
DR   Cosmic; 1152121
DR   Cosmic; 1239983
DR   Cosmic; 1280049
DR   Cosmic; 1507378
DR   Cosmic; 1533555
DR   Cosmic; 1536131
DR   Cosmic; 1889010
DR   Cosmic; 2054101
DR   Cosmic; 2319854
DR   Cosmic; 2791087
DR   IARC_TP53; 27016
DR   Wikidata; Q54899531
RX   PubMed=18713817;
RX   PubMed=19825993;
RX   PubMed=21868764;
RX   PubMed=23833040;
RX   PubMed=30737244;
CC   Sequence variation: Mutation; HGNC; HGNC:7230; MRE11; Simple; p.Leu57Ter (c.170T>G); ClinVar=VCV000479719; Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly199Val (c.596G>T); ClinVar=VCV000451799; Zygosity=Homozygous (PubMed=19825993; PubMed=30737244).
CC   Omics: Transcriptomics; Microarray.
ST   Source(s): PubMed=18713817; PubMed=21868764; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 30,31
ST   D3S1358: 15
ST   D5S818: 10,12
ST   D7S820: 10
ST   D8S1179: 14,16
ST   FGA: 20,21
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 22
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=19825993; DOI=10.1158/1541-7786.MCR-09-0117;
RA   Kim T.-H., Lee S.Y., Rho J.H., Jeong N.Y., Soung Y.H., Jo W.S.,
RA   Kang D.-Y., Kim S.-H., Yoo Y.H.;
RT   "Mutant p53 (G199V) gains antiapoptotic function through signal
RT   transducer and activator of transcription 3 in anaplastic thyroid
RT   cancer cells.";
RL   Mol. Cancer Res. 7:1645-1654(2009).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//